Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
TransCode Therapeutics, Inc. logo — Delivering a cancer-free future

TransCode Therapeutics, Inc.

Delivering a cancer-free future

Founded 2016 United States Newton, United States 11 employees Post-IPO Equity Total: $28.05M Biotechnology, Health Care +1

General Information

Company Name TransCode Therapeutics, Inc.
Founded Year 2016
Location United States Newton, United States
Employees 11
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with TransCode Therapeutics, Inc.. To contact TransCode Therapeutics, Inc., visit transcodetherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does TransCode Therapeutics, Inc. compare?

A PDF of TransCode Therapeutics, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting TransCode Therapeutics, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a biotechnology startup founded in 2016, with a mission to deliver a cancer-free future for all cancer patients. The company focuses on the intelligent design and efficient delivery of targeted therapeutics, particularly TTX-MC138, which targets microRNA-10b, considered the master regulator of metastatic cell viability in various cancers. Additionally, TransCode has preclinical programs such as TTX-siPDL1 and TTX-siLIN28B for solid tumor treatment, and cancer agnostic programs including TTX-RIGA, TTX-CRISPR, and TTX-mRNA. The company has recently received a $7.25M Post-IPO Equity investment on 18 January 2024, indicating investor confidence in its potential. TransCode's proprietary delivery platform, TTX, enables the transport of targeted therapeutics to cancer cells, offering a solution to the challenge of delivery in cancer therapy. With a rapidly expanding platform of drug candidates and a world-class team, TransCode aims to target a variety of tumor indications with the goal of long-term treatment survival. The company's focus on addressing the highest unmet need in cancer treatment makes it an intriguing prospect for investors in the health care and biotechnology industries.

Business keywords: cancer therapeutics, targeted therapies, biomarker targeting, RNA-based therapies, gene therapy, oncology research, drug delivery technology, microRNA-10b, PD-L1 modulation, CRISPR/Cas9, cancer vaccine development, tumor microenvironment, cancer treatment innovation, precision medicine, immunotherapy

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $3.00M -
22 Jul 2024
Post IPO Equity $7.25M -
18 Jan 2024
Post IPO Equity $1.20M -
30 Nov 2023
Post IPO Equity Undisclosed -
26 Oct 2023
Post IPO Equity $8.50M -
25 Sep 2023
Post IPO Equity $7.00M -
06 Jun 2023
Post IPO Equity Undisclosed 1
Triton Funds
Triton Funds
03 Apr 2023
Grant $1.10M 1
National Cancer Institute
01 Jun 2022
Post IPO Equity Undisclosed 1
Red Cedar Ventures
Red Cedar Ventures
12 Jul 2021
Seed Round Undisclosed 1
Red Cedar Ventures
Red Cedar Ventures
04 Aug 2014

TransCode Therapeutics, Inc. Alternatives & Competitors

View All Alternatives
TransCode Therapeutics, Inc. vs
Curamir Therapeutics, Inc.
Curamir Therapeutics, Inc. United States

Finding RNA-targeted cures for cancer.

Series A
1 employees
Biotechnology, Health and Wellness
TransCode Therapeutics, Inc. vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post-IPO Equity
157 employees
Biotechnology, Health Care
Compare TransCode Therapeutics, Inc. vs Tango Therapeutics
TransCode Therapeutics, Inc. vs
Inspirna, Inc.
Inspirna, Inc. United States

Converting cancer to a manageable, chronic condition

Series D
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About TransCode Therapeutics, Inc.

Delivering a cancer-free future
TransCode Therapeutics, Inc. was founded in 2016.
TransCode Therapeutics, Inc. is headquartered in Newton, United States.
TransCode Therapeutics, Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on cancer therapeutics, targeted therapies, biomarker targeting and RNA-based therapies.
TransCode Therapeutics, Inc. has approximately 11 employees.
TransCode Therapeutics, Inc. has completed 10 funding rounds, raising a total of $28.05M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to TransCode Therapeutics, Inc. include Curamir Therapeutics, Inc., Tango Therapeutics, Inspirna, Inc., ONK Therapeutics, Bound Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TransCode Therapeutics, Inc. and Curamir Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TransCode Therapeutics, Inc., https://bouncewatch.com/company/transcode-therapeutics-inc, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout